Phencyclidine, the drug induces psychosis: Its neuropharmacological actions

Toshitaka Nabeshima, H. Furukawa, T. Kameyama

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Phencyclidine (PCP) is a major drug of abuse as well as a 'drug of choice' among substance abusers in the U.S. PCP use may result in the development of psychotic behavior. PCP-induced psychosis is characterized by confusion, excitation, aggression, paranoia, hallucinations and delusions of grandeur and may evoke violent or suicidal behavior. Therefore, many patients from PCP-induced psychosis have been diagnosed initially as schizophrenic. However, PCP-related research has not kept pace with the rise in abuse and PCP-induced psychosis. The neurochemical effects of PCP are not well defined at present, but both behavioral and biochemical studies suggest that it may interact with dopaminergic, cholinergic, noradrenergic, serotonergic, GABAergic and enkephalinergic systems. The specific reversible, saturable, high affinity 3H-PCP binding site was discovered recently in rat brain. There is now a large body of evidence to suggest that opiate receptors may be subdivided into mu, sigma, kappa and delta receptors. On the basis of behavioral and binding studies, it is proposed that the sigma receptor and the PCP binding site are one and the same. This receptor interacts with PCP and psychotomimetic epioids to produce their psychotomimetic effects. This review has served to illustrate the paucity of information currently available on the central effects of PCP. However, our current notions of the mechanisms of action of PCP are very complicated. Such a review inevitably raises more questions than it answers but it is hoped that these may stimulate further investigation in this field.

Original languageEnglish
Pages (from-to)133-147
Number of pages15
JournalJapanese Journal of Psychopharmacology
Volume4
Issue number2
Publication statusPublished - 01-12-1984
Externally publishedYes

Fingerprint

Substance-Induced Psychoses
Phencyclidine
Psychotic Disorders
sigma Receptors
Phencyclidine Abuse
Binding Sites
Paranoid Disorders
Confusion
kappa Opioid Receptor
delta Opioid Receptor
Delusions
mu Opioid Receptor
Hallucinations
Street Drugs
Opioid Receptors
Aggression
Cholinergic Agents
Brain
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{cba824ef60ce46c6be83d020574e0557,
title = "Phencyclidine, the drug induces psychosis: Its neuropharmacological actions",
abstract = "Phencyclidine (PCP) is a major drug of abuse as well as a 'drug of choice' among substance abusers in the U.S. PCP use may result in the development of psychotic behavior. PCP-induced psychosis is characterized by confusion, excitation, aggression, paranoia, hallucinations and delusions of grandeur and may evoke violent or suicidal behavior. Therefore, many patients from PCP-induced psychosis have been diagnosed initially as schizophrenic. However, PCP-related research has not kept pace with the rise in abuse and PCP-induced psychosis. The neurochemical effects of PCP are not well defined at present, but both behavioral and biochemical studies suggest that it may interact with dopaminergic, cholinergic, noradrenergic, serotonergic, GABAergic and enkephalinergic systems. The specific reversible, saturable, high affinity 3H-PCP binding site was discovered recently in rat brain. There is now a large body of evidence to suggest that opiate receptors may be subdivided into mu, sigma, kappa and delta receptors. On the basis of behavioral and binding studies, it is proposed that the sigma receptor and the PCP binding site are one and the same. This receptor interacts with PCP and psychotomimetic epioids to produce their psychotomimetic effects. This review has served to illustrate the paucity of information currently available on the central effects of PCP. However, our current notions of the mechanisms of action of PCP are very complicated. Such a review inevitably raises more questions than it answers but it is hoped that these may stimulate further investigation in this field.",
author = "Toshitaka Nabeshima and H. Furukawa and T. Kameyama",
year = "1984",
month = "12",
day = "1",
language = "English",
volume = "4",
pages = "133--147",
journal = "Neuropsychopharmacology Reports",
issn = "1340-2544",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

Phencyclidine, the drug induces psychosis : Its neuropharmacological actions. / Nabeshima, Toshitaka; Furukawa, H.; Kameyama, T.

In: Japanese Journal of Psychopharmacology, Vol. 4, No. 2, 01.12.1984, p. 133-147.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Phencyclidine, the drug induces psychosis

T2 - Its neuropharmacological actions

AU - Nabeshima, Toshitaka

AU - Furukawa, H.

AU - Kameyama, T.

PY - 1984/12/1

Y1 - 1984/12/1

N2 - Phencyclidine (PCP) is a major drug of abuse as well as a 'drug of choice' among substance abusers in the U.S. PCP use may result in the development of psychotic behavior. PCP-induced psychosis is characterized by confusion, excitation, aggression, paranoia, hallucinations and delusions of grandeur and may evoke violent or suicidal behavior. Therefore, many patients from PCP-induced psychosis have been diagnosed initially as schizophrenic. However, PCP-related research has not kept pace with the rise in abuse and PCP-induced psychosis. The neurochemical effects of PCP are not well defined at present, but both behavioral and biochemical studies suggest that it may interact with dopaminergic, cholinergic, noradrenergic, serotonergic, GABAergic and enkephalinergic systems. The specific reversible, saturable, high affinity 3H-PCP binding site was discovered recently in rat brain. There is now a large body of evidence to suggest that opiate receptors may be subdivided into mu, sigma, kappa and delta receptors. On the basis of behavioral and binding studies, it is proposed that the sigma receptor and the PCP binding site are one and the same. This receptor interacts with PCP and psychotomimetic epioids to produce their psychotomimetic effects. This review has served to illustrate the paucity of information currently available on the central effects of PCP. However, our current notions of the mechanisms of action of PCP are very complicated. Such a review inevitably raises more questions than it answers but it is hoped that these may stimulate further investigation in this field.

AB - Phencyclidine (PCP) is a major drug of abuse as well as a 'drug of choice' among substance abusers in the U.S. PCP use may result in the development of psychotic behavior. PCP-induced psychosis is characterized by confusion, excitation, aggression, paranoia, hallucinations and delusions of grandeur and may evoke violent or suicidal behavior. Therefore, many patients from PCP-induced psychosis have been diagnosed initially as schizophrenic. However, PCP-related research has not kept pace with the rise in abuse and PCP-induced psychosis. The neurochemical effects of PCP are not well defined at present, but both behavioral and biochemical studies suggest that it may interact with dopaminergic, cholinergic, noradrenergic, serotonergic, GABAergic and enkephalinergic systems. The specific reversible, saturable, high affinity 3H-PCP binding site was discovered recently in rat brain. There is now a large body of evidence to suggest that opiate receptors may be subdivided into mu, sigma, kappa and delta receptors. On the basis of behavioral and binding studies, it is proposed that the sigma receptor and the PCP binding site are one and the same. This receptor interacts with PCP and psychotomimetic epioids to produce their psychotomimetic effects. This review has served to illustrate the paucity of information currently available on the central effects of PCP. However, our current notions of the mechanisms of action of PCP are very complicated. Such a review inevitably raises more questions than it answers but it is hoped that these may stimulate further investigation in this field.

UR - http://www.scopus.com/inward/record.url?scp=0021718289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021718289&partnerID=8YFLogxK

M3 - Review article

C2 - 6395556

AN - SCOPUS:0021718289

VL - 4

SP - 133

EP - 147

JO - Neuropsychopharmacology Reports

JF - Neuropsychopharmacology Reports

SN - 1340-2544

IS - 2

ER -